Targeted therapy--possible new therapeutic option for malignant mesothelioma?
Malignant Mesothelioma presents with a characteristic heterogeneous growth pattern. Response to treatment is often only partial, which may be related to tumor cell heterogeneity. Molecular screening methods have revealed profound differences in the driving mechanisms of the variously differentiated mesothelioma cells. Characterization of these differences has made it possible to identify novel drug targets which are effective for both phenotypes.
Dobra
Katalin
K
Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden. katalin.dobra@ki.se
Hjerpe
Anders
A
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001897:Boronic Acids / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008654:Mesothelioma / Q000378:metabolism* / Q000473:pathology*; D009844:Oligosaccharides / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D011509:Proteoglycans / Q000378:metabolism*; D011719:Pyrazines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D018038:Sodium Selenite / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013879:Thioredoxins / Q000378:metabolism*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D009844:Oligosaccharides; D011509:Proteoglycans; D011719:Pyrazines; D013879:Thioredoxins; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex; D018038:Sodium Selenite